A phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castrate resistant prostate cancer (mCRPC)

被引：0

作者：

Carducci, M. ^{[1
]}

Armstrong, A. ^{[2
,3
]}

Pili, R. ^{[4
]}

Ng, S. ^{[5
]}

Huddart, R. ^{[6
]}

Agarwal, N. ^{[7
]}

Khvorostenko, D. ^{[8
]}

Lyulko, O. ^{[9
]}

Brize, A. ^{[10
]}

Vogelzang, N. J. ^{[11
]}

Delva, R. ^{[12
]}

Harza, M. ^{[13
]}

Thanos, A. ^{[14
]}

James, N. ^{[15
]}

Werbrouck, P. ^{[16
]}

Boegemann, M. ^{[17
]}

Hutson, T. ^{[18
]}

Milecki, P. ^{[19
]}

Nederman, T. ^{[20
]}

Sternberg, C. ^{[21
]}

机构：

[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[2] Duke Canc Inst, Div Med Oncol, Durham, NC USA

[3] Duke Canc Inst, Div Urol, Durham, NC USA

[4] Indiana Univ Sch Med, Div Hematol Oncol, Dept Med, Indianapolis, IN 46202 USA

[5] St John God Hosp, Ivy Suite Canc Ctr, Subiaco, WA, Australia

[6] Royal Marsden Hosp, Clin Oncol, Sutton, Surrey, England

[7] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[8] Leningrad Reg Oncol Dispensary, St Petersburg, Russia

[9] Municipal Inst Zaporizhzhia Reg Clin Hosp, Dept Urol, Zaporizhzhya, Ukraine

[10] Riga Eastern Clin Univ Hosp, Latvian Oncol Ctr, Riga, Latvia

[11] US Oncol & Comprehens Canc Ctr Nevada, Med Oncol, Las Vegas, NV USA

[12] Ctr Reg Lutte Canc Paul Papin, Serv Oncol Med, Angers, France

[13] Fundeni Clin Inst, Dept Urol, Bucharest, Romania

[14] Hosp Athens, Urol Clin, Agios Savas Anticanc Oncol, Athens, Greece

[15] Univ Warwick, Canc Res Unit, Warwick, England

[16] AZ Groeninge, Dept Urol, Kortrijk, Belgium

[17] Univ Klinikum Munster, Klin & Polikklin Urol, Munster, Germany

[18] Texas Oncol PA, Collins Bldg, Dallas, TX USA

[19] Wielkopolskie Ctr Onkol, Dept Radiotherapy, Poznan, Poland

[20] Act Biotech AB, Clin Dev, Lund, Sweden

[21] San Camillo & Forlanini Hosp, Dept Med Oncol, Rome, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)31934-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4BA

引用

页码：S713 / S714

页数：2

共 50 条

[1] A Phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castration-resistant prostate cancer (mCRPC), secondary endpoints.
Sternberg, Cora N.
Armstrong, Andrew J.
Pili, Roberto
Nederman, Tore
Carducci, Michael Anthony
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
[2] Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Pili, Roberto
Haggman, Michael
Stadler, Walter M.
Gingrich, Jeffrey R.
Assikis, Vasileios J.
Bjork, Anders
Nordle, Orjan
Forsberg, Goran
Carducci, Michael A.
Armstrong, Andrew J.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (30) : 4022 - 4028
[3] Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer
Sternberg, Cora
Armstrong, Andrew
Pili, Roberto
Ng, Siobhan
Huddart, Robert
Agarwal, Neeraj
Khvorostenko, Denis
Lyulko, Olexiy
Brize, Arija
Vogelzang, Nicholas
Delva, Remy
Harza, Mihai
Thanos, Anastasios
James, Nicholas
Werbrouck, Patrick
Boegemann, Martin
Hutson, Thomas
Milecki, Piotr
Chowdhury, Simon
Gallardo, Enrique
Schwartsmann, Gilberto
Pouget, Jean-Christophe
Baton, Frederique
Nederman, Thore
Tuvesson, Helen
Carducci, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (22) : 2636 - U136
[4] Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC).
Monk, Paul
Liu, Glenn
Stadler, Walter Michael
Geyer, Susan Michelle
Sexton, Jennifer L.
Wright, John Joseph
Villalona-Calero, Miguel Angel
Wade, James Lloyd
Szmulewitz, Russell Zelig
Gupta, Shilpa
Mortazavi, Amir
Dreicer, Robert
Pili, Roberto
Cooney, Matthew M.
Dawson, Nancy Ann
George, Saby
Garcia, Jorge A.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
[5] Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)
Paul Monk
Glenn Liu
Walter M. Stadler
Susan Geyer
Ying Huang
John Wright
Miguel Villalona-Calero
James Wade
Russell Szmulewitz
Shilpa Gupta
Amir Mortazavi
Robert Dreicer
Roberto Pili
Nancy Dawson
Saby George
Jorge A. Garcia
Investigational New Drugs, 2018, 36 : 919 - 926
[6] Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)
Monk, Paul
Liu, Glenn
Stadler, Walter M.
Geyer, Susan
Huang, Ying
Wright, John
Villalona-Calero, Miguel
Wade, James
Szmulewitz, Russell
Gupta, Shilpa
Mortazavi, Amir
Dreicer, Robert
Pili, Roberto
Dawson, Nancy
George, Saby
Garcia, Jorge A.
INVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 919 - 926
[7] A randomized, double-blind, placebo-controlled phase II study of testosterone replacement in men with asymptomatic castrate-resistant prostate cancer (PC)
Szmulewitz, R. Z.
Posadas, E. M.
Manchen, B.
Stadler, W. M.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[8] Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)
Armstrong, Andrew J.
Kaboteh, Reza
Carducci, Michael A.
Damber, Jan-Erik
Stadler, Walter M.
Hansen, Mats
Edenbrandt, Lars
Forsberg, Goran
Nord, Orjan
Pili, Roberto
Morris, Michael J.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (08) : 1308 - 1316
[9] Concurrent high-dose IV Vitamin C (IVC) and docetaxel for metastatic castrate-resistant prostate cancer (mCRPC): A randomized, placebo-controlled, double-blind phase II trial
Paller, C.
Zahurek, M.
Mandl, A.
Rudek, M.
Heath, E.
Marshall, C. H.
Markowski, M. C.
Lalji, A.
Metri, N.
Hoimes, C. J.
Taksey, J.
Durham, J.
Kelly, W.
Antonarakis, E. S.
Eisenberger, M.
Carducci, M. A.
Denmeade, S.
Levine, M.
ANNALS OF ONCOLOGY, 2023, 34 : S992 - S992
[10] Randomized, double-blind, placebo-controlled proof of concept study of tasquinimod maintenance therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) who experience response or stabilization during first-line docetaxel chemotherapy.
Fizazi, Karim
Heidenreich, Axel
Daugaard, Gedske
Bellmunt, Joaquim
Germann, Nathalie
Chetaille, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

← 1 2 3 4 5 →